For example, patients with AML M3 (acute promyelocytic leukemia) showed a decreased expression of the activating NKG2D receptor, while all AML patients displayed an overexpression of the inhibitory receptors CD158b and NKG2A compared to healthy controls [85]. This evidence concerns the gene KLRC1 and acute myeloid leukemia.